Letter from the Editor

Contributed by:

Taren Grom, Editor

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

Leading from the top

Disruption, our experts say in this month’s cover article, is required for the industry to move forward, particularly in light of multiple industry forces. Bernard Munos, senior fellow at FasterCures, Milken Institute, doesn’t like to use the word disruption, because it scares people; he prefers the word transformation in describing the changes taking place in the industry.
Mr. Munos believes disruption is happening because the industry’s business model has aged to the point where resources — time and money — are being squandered in vast amounts. Chris Cullmann, senior VP, Engagement Strategy, Ogilvy CommonHealth Worldwide, notes that disruption is a loaded term — one that carries with it a lot of cultural baggage. He says to truly call something disruptive requires that it cannot be “unseen.” It needs to be a change of such significance, that to turn back is not a practical consideration and that going forward, people can use this disruption. We tapped a dozen other industry experts to get their insights on how they define disruption and what it will take to fuel innovation going forward.

A new survey from McKinsey suggests that for companies to successfully transform, organizations need employee buy-in at all levels, consistent communication, and better people strategies.

Organizational transformations are hard work, and according to the latest McKinsey Global Survey on the topic, companies are no more successful at overhauling their performance and organizational health than they were 10 years ago. A particular blind spot seems to be the failure to involve front-line employees and their managers in the effort.

Craig Lipset, head of clinical innovation, global product development, Pfizer, says his company has invested significantly in making sure that it has the right clinicians, technologists, and engineers to execute around its innovative platforms, such as Blue Sky. He says bringing the right talent together created more diverse teams in terms of  new skills, roles, and thinking.

In response to some of the challenges that the McKinsey survey results revealed, here are a few steps that companies can take to support the success of their transformations:
•    Show — don’t tell — progress to the front line. When large companies embark on a transformation, there is a risk that front-line employees will see only the individual pain and not the aggregate gain.
•    Involve HR as a strategic partner. Transformations have a significant impact on employees and therefore require active involvement from human resources.
•    Engage employees through new channels. The survey results suggest that reaching the front line is a greater-than-average challenge at larger companies.

Let us know how your company is addressing transformation; shoot me an email: tgrom@pharmavoice.com.

Taren Grom, Editor


Their word…

Denise Myshko
Managing Editor

Pharmaceutical companies are adopting innovative clinical trial designs as a way to increase efficiency and reduce costs.

Robin Robinson
Senior Editor

As the life-sciences industry embraces disruptive technology, it will find more opportunity to streamline all processes.

Kim Ribbink
Features Editor

Any marketing initiative in rare diseases must put the patients and their caregivers front and center.

Coming in April 2017  special issue

A New Era of Collaboration
• Trends
• Success Factors
• Key Learnings
• Opportunities
• Partnerships
Showcase Feature: Global Markets



Volume 17 • Number 3
Publisher    Lisa Banket
Editor    Taren Grom
Creative Director    Marah Walsh

Managing Editor
Denise Myshko

Senior Editor
Robin Robinson

Features Editor
Kim Ribbink

Design Associate
Ariel Medel

Director of Sales
Cathy Tracy

National Account Manager
Suzanne Besse

Webcast Network Producer
Daniel Limbach

Circulation Assistant
Kathy Deiuliis

Copyright 2017
by PharmaLinx LLC, Titusville, NJ
Printed in the U.S.A.
Volume Seventeen, Number Three

PharmaVoice (ISSN: 1932961X) is published monthly except joint issues in July/Aug. and Nov./Dec., by ­Pharma­­Linx LLC, P.O. Box 327, Titusville, NJ 08560. ­Periodicals postage paid at Titusville, NJ 08560 and additional mailing offices.

Postmaster: Send address changes to PharmaVOICE, P.O. Box 292345, Kettering, OH 45429-0345.

PharmaVoice Coverage and Distribution:
Domestic subscriptions are available at $190 for one year (10 issues). Foreign subscriptions: 10 issues US$360. Contact PharmaVoice at P.O. Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your order to 609.730.0197.

Contributions: PharmaVoice is not responsible for unsolicited contributions of any type. Unless otherwise agreed in writing, PharmaVoice retains all rights on material published in PharmaVoice for a period of six months after publication and reprint rights after that period expires. E-mail: tgrom@pharmavoice.com.

Change of address: Please allow six weeks for a change of address. Send your new address along with your subscription label to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345. Call us at 800.607.4410 or FAX your change to 937.890.0221. E-mail: mwalsh@pharmavoice.com.

Important notice: The post office will not forward copies of this magazine. PharmaVoice is not responsible for replacing undelivered copies due to lack of or late notification of address change.

Advertising in PharmaVoice: To advertise in Pharma­­Voice please contact our Advertising ­Department at P.O. Box 327, Titusville, NJ 08560, or ­telephone us at 609.730.0196. E-mail: lbanket@pharmavoice.com.

Posted in:

Post a Comment

You must be logged in to post a Comment.